Openbookopenbook
Equity
DRUG
+0.0 · +0.00%
USD · NASDAQ

Bright Minds Biosciences Inc(DRUG) Stock Analysis | Healthcare

USD --+0.00%
Reward30Low
Risk29Low
75%Data
Capital Destroyer
Market Cap:714.42M
ⓘ
Reward Rating
30
Low
Reward Assessment
75% data coverage
Bottom 1% of stocksView factors
ⓘ
Risk Rating
29
Low
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on DRUG to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for DRUG, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $169.49.

What is Bright Minds Biosciences Inc?

, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.

DRUG · Verdict

Limited reward · low risk

DRUG stands out on volatility and balance sheet, but watch the cash flow signal.

Based on 88% data coverage

DRUG · Verdict

What’s working & what to watch

Strengths 2

  • Volatility95/100

    Top decile vs peers

  • Balance sheet76/100

    Current ratio 36.10

Watchouts 3

  • Cash flow5/100

    Weak vs peers

  • Profitability10/100

    -14% return on equity

  • Growth16/100

    Earnings -6.5% CAGR

Model-based scoring. For information only — not financial advice.

What is Bright Minds Biosciences Inc?

, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 714.42M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (30)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

CTMXSmall Cap / 715M market cap
CytomX Therapeutics Inc
Compare
ATXSSmall Cap / 718M market cap
Astria Therapeutics Inc
Compare
RGNXSmall Cap / 711M market cap
Regenxbio Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap714.42M
P/E RatioN/A
Dividend YieldN/A
Beta0.091
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.